

REMARKS

Claims 9-11, 18, 19, 22 and 23 are pending in the present application. Claims 1-8, 12-17, and 20-21 are cancelled. Claim 23 is currently amended to be dependant on claim 9 instead of claim 1, which was previously cancelled. Claims 10, 18, 19, and 22 are currently withdrawn, in light of the election of Group I herein.

No new matter has been introduced by virtue of the amendments made herein. Accordingly, applicants respectfully request their entry.

Restriction Requirement under 35 U.S.C § 121

In the August 1, 2005 communication, the Examiner requested Applicants to elect between Groups I-V.

In response, Applicants hereby elect with Group I, 9 (in part), 11 (in part), and 23 (in part), drawn to pyrazolo[1,5-a]pyrimidines (A = K = G = E = C and J = D = N), classified in class 544, subclass 281, with traverse.

Applicants' election of Group I at present, however, does not prejudice Applicants' ability to file divisional or continuation applications to unelected subject matter.

Applicants do not believe any additional fees are due in connection with the filing of this response to the August 1, 2005 communication. However, if any fee is due, the Examiner is authorized to charge the fee to applicants' Deposit Account No. 16-1445.

CONCLUSION

Applicants respectfully request prompt consideration of the pending claims and early allowance of the application.

Date:

10/13/05

Respectfully submitted,



Jason G. Tebbutt
Attorney for Applicant(s)
Reg. No. 55,671

Jolene Appleman
Attorney for Applicant(s)
Reg. No. 35,428



Pfizer, Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-4827

Patent Application 10/762,742
Attorney Docket No. PC9574C